Synergistic Antimicrobial and Antiviral Efficacy of Chitosan-Silver Nanocomposites Against Major Pathogens of Bombyx mori: In Vitro and In Vivo Evaluations

壳聚糖-银纳米复合材料对家蚕主要病原体的协同抗菌和抗病毒功效:体外和体内评价

阅读:1

Abstract

Diseases caused by pathogenic microorganisms in Bombyx mori have long been a major constraint on the sustainable development of sericulture. Current preventive strategies remain substantially constrained by issues of drug resistance and environmental compatibility. In recent years, the application of nanomaterials for pathogenic microorganism control has garnered escalating attention. Among these, chitosan-silver nanoparticles (CS-Ag NPs), as an emerging class of nanocomposites, integrate the biocompatibility and biodegradability of chitosan with the robust antimicrobial activity of silver nanoparticles, thereby exhibiting considerable potential for preventing pathogenic infections. Nevertheless, the efficacy of CS-Ag NPs against B. mori pathogens has not previously been documented. In this study, CS-Ag NPs were successfully synthesized via chemical reduction. Their antiviral activity was validated using quantitative PCR. The inhibitory efficacy of CS-Ag NPs against Bacillus bombysepticus and Serratia marcescens was evaluated through in vitro inhibition zone assays and bacterial growth curve analysis, with the minimum inhibitory (MIC) concentration for both pathogens determined. Notably, CS-Ag NPs exhibited no significant inhibitory effect on filamentous fungi, potentially due to the impaired ability of nanoparticles to penetrate fungal cell walls. Preliminary mechanistic investigations into the antimicrobial mechanism of CS-Ag NPs were conducted from the perspectives of oxidative stress. Our data showed that CS-Ag NPs could effectively alleviate ROS accumulation induced by the pathogen. In summary, our work systematically investigates the potential of CS-Ag NPs in controlling pathogens and enables the preliminary elucidation of their antibacterial mechanisms. These findings establish a theoretical foundation for the development of pharmaceuticals against pathogenic microorganisms and also offer novel insights into the ecofriendly management of diseases.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。